114 related articles for article (PubMed ID: 31356696)
1. Integrating resistance functions to predict response to induction chemotherapy in de novo acute myeloid leukemia.
Chiu YC; Hsiao TH; Tsai JR; Wang LJ; Ho TC; Hsu SL; Teng CJ
Eur J Haematol; 2019 Oct; 103(4):417-425. PubMed ID: 31356696
[TBL] [Abstract][Full Text] [Related]
2. Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.
Ragusa M; Avola G; Angelica R; Barbagallo D; Guglielmino MR; Duro LR; Majorana A; Statello L; Salito L; Consoli C; Camuglia MG; Di Pietro C; Milone G; Purrello M
BMC Cancer; 2010 Jul; 10():377. PubMed ID: 20642818
[TBL] [Abstract][Full Text] [Related]
3. Gene expression profiling of acute myeloid leukemia samples from adult patients with AML-M1 and -M2 through boutique microarrays, real-time PCR and droplet digital PCR.
Handschuh L; Kaźmierczak M; Milewski MC; Góralski M; Łuczak M; Wojtaszewska M; Uszczyńska-Ratajczak B; Lewandowski K; Komarnicki M; Figlerowicz M
Int J Oncol; 2018 Mar; 52(3):656-678. PubMed ID: 29286103
[TBL] [Abstract][Full Text] [Related]
4. Chemoresistance in acute myeloid leukemia: An alternative single-cell RNA sequencing approach.
Cheng PL; Hsiao TH; Chen CH; Hung MN; Jhan PP; Lee LW; Wu TS; Tsai JR; Teng CJ
Hematol Oncol; 2023 Aug; 41(3):499-509. PubMed ID: 36790759
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
6. Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience.
Gbadamosi B; Ezekwudo D; Bastola S; Jaiyesimi I
Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):e287-e294. PubMed ID: 29803615
[TBL] [Abstract][Full Text] [Related]
7. Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.
Cesano A; Willman CL; Kopecky KJ; Gayko U; Putta S; Louie B; Westfall M; Purvis N; Spellmeyer DC; Marimpietri C; Cohen AC; Hackett J; Shi J; Walker MG; Sun Z; Paietta E; Tallman MS; Cripe LD; Atwater S; Appelbaum FR; Radich JP
PLoS One; 2015; 10(4):e0118485. PubMed ID: 25884949
[TBL] [Abstract][Full Text] [Related]
8. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
9. Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia.
Bertoli S; Paubelle E; Bérard E; Saland E; Thomas X; Tavitian S; Larcher MV; Vergez F; Delabesse E; Sarry A; Huguet F; Larrue C; Bosc C; Farge T; Sarry JE; Michallet M; Récher C
Eur J Haematol; 2019 Feb; 102(2):131-142. PubMed ID: 30325535
[TBL] [Abstract][Full Text] [Related]
10. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia.
Heuser M; Wingen LU; Steinemann D; Cario G; von Neuhoff N; Tauscher M; Bullinger L; Krauter J; Heil G; Döhner H; Schlegelberger B; Ganser A
Haematologica; 2005 Nov; 90(11):1484-92. PubMed ID: 16266895
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
Nakano H; Fujiwara SI; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
Hematol Oncol; 2017 Sep; 35(3):357-364. PubMed ID: 26639319
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.
Song LX; Xu L; Li X; Chang CK; Zhang Y; Wu LY; He Q; Zhang QX; Li X
Ann Hematol; 2012 Dec; 91(12):1879-86. PubMed ID: 22895556
[TBL] [Abstract][Full Text] [Related]
13. Long non-coding RNA taurine-upregulated gene 1 correlates with unfavorable prognosis in patients with refractory or relapsed acute myeloid leukemia treated by purine analogue based chemotherapy regimens.
Luo W; Yu H; Zou X; Ni X; Wei J
Cancer Biomark; 2018; 23(4):485-494. PubMed ID: 30347595
[TBL] [Abstract][Full Text] [Related]
14. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
[TBL] [Abstract][Full Text] [Related]
15. High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.
Zhang TJ; Lin J; Zhou JD; Li XX; Zhang W; Guo H; Xu ZJ; Yan Y; Ma JC; Qian J
Gene; 2018 Jan; 640():79-85. PubMed ID: 29032147
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CD95, Bcl-2 and Bax expression and CD95 function in adult de novo acute myeloid leukemia in context of P-glycoprotein function, maturation stage, and cytogenetics.
Wuchter C; Karawajew L; Ruppert V; Büchner T; Schoch C; Haferlach T; Ratei R; Dörken B; Ludwig WD
Leukemia; 1999 Dec; 13(12):1943-53. PubMed ID: 10602414
[TBL] [Abstract][Full Text] [Related]
17. A precision medicine test predicts clinical response after idarubicin and cytarabine induction therapy in AML patients.
Martínez-Cuadrón D; Gil C; Serrano J; Rodríguez G; Pérez-Oteyza J; García-Boyero R; Jiménez-Bravo S; Vives S; Vidriales MB; Lavilla E; Pérez-Simón JA; Tormo M; Colorado M; Bergua J; López JA; Herrera P; Hernández-Campo P; Gorrochategui J; Primo D; Rojas JL; Villoria J; Moscardó F; Troconiz I; Linares Gómez M; Martínez-López J; Ballesteros J; Sanz M; Montesinos P;
Leuk Res; 2019 Jan; 76():1-10. PubMed ID: 30468991
[TBL] [Abstract][Full Text] [Related]
18. A scoring system to predict the risk of death during induction with anthracycline plus cytarabine-based chemotherapy in patients with de novo acute myeloid leukemia.
Valcárcel D; Montesinos P; Sánchez-Ortega I; Brunet S; Esteve J; Martínez-Cuadrón D; Ribera JM; Tormo M; Bueno J; Duarte R; Llorente A; Torres JP; Guardia R; Sanz MA; Sierra AJ;
Cancer; 2012 Jan; 118(2):410-7. PubMed ID: 21717435
[TBL] [Abstract][Full Text] [Related]
19. Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy.
Lazzarotto D; Candoni A; Nadali G; Pavan L; Lessi F; Mosna F; Simeone E; Ventura G; Gherlinzoni F; Semenzato G; Pizzolo G; Fanin R
Eur J Haematol; 2016 Jun; 96(6):586-92. PubMed ID: 26186084
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia.
Liu H; Fu R; Li L; Wang G; Song J; Ruan E; Wang H; Wu Y; Wang X; Ding K; Shao Z
Clin Drug Investig; 2017 Feb; 37(2):167-174. PubMed ID: 27722823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
